Literature DB >> 28653853

Post-Translational Modifications (PTMs), Identified on Endogenous Huntingtin, Cluster within Proteolytic Domains between HEAT Repeats.

Tamara Ratovitski1, Robert N O'Meally2, Mali Jiang1, Raghothama Chaerkady2, Ekaterine Chighladze1, Jacqueline C Stewart1, Xiaofang Wang1, Nicolas Arbez1, Elaine Roby1, Athanasios Alexandris1, Wenzhen Duan1,3,4, Ravi Vijayvargia5,6, Ihn Sik Seong5,6, Daniel J Lavery7, Robert N Cole2, Christopher A Ross1,3,4.   

Abstract

Post-translational modifications (PTMs) of proteins regulate various cellular processes. PTMs of polyglutamine-expanded huntingtin (Htt) protein, which causes Huntington's disease (HD), are likely modulators of HD pathogenesis. Previous studies have identified and characterized several PTMs on exogenously expressed Htt fragments, but none of them were designed to systematically characterize PTMs on the endogenous full-length Htt protein. We found that full-length endogenous Htt, which was immunoprecipitated from HD knock-in mouse and human post-mortem brain, is suitable for detection of PTMs by mass spectrometry. Using label-free and mass tag labeling-based approaches, we identified near 40 PTMs, of which half are novel (data are available via ProteomeXchange with identifier PXD005753). Most PTMs were located in clusters within predicted unstructured domains rather than within the predicted α-helical structured HEAT repeats. Using quantitative mass spectrometry, we detected significant differences in the stoichiometry of several PTMs between HD and WT mouse brain. The mass-spectrometry identification and quantitation were verified using phospho-specific antibodies for selected PTMs. To further validate our findings, we introduced individual PTM alterations within full-length Htt and identified several PTMs that can modulate its subcellular localization in striatal cells. These findings will be instrumental in further assembling the Htt PTM framework and highlight several PTMs as potential therapeutic targets for HD.

Entities:  

Keywords:  Huntington’s disease; TMT; human brain; mass spectrometry; neurodegenerative disorder; post-translational modifications

Mesh:

Substances:

Year:  2017        PMID: 28653853      PMCID: PMC5560079          DOI: 10.1021/acs.jproteome.6b00991

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  58 in total

1.  Mass spectrometric identification of novel posttranslational modification sites in Huntingtin.

Authors:  Gaofeng Dong; Eduardo Callegari; Christian J Gloeckner; Marius Ueffing; Hongmin Wang
Journal:  Proteomics       Date:  2012-06       Impact factor: 3.984

2.  Options and considerations when selecting a quantitative proteomics strategy.

Authors:  Bruno Domon; Ruedi Aebersold
Journal:  Nat Biotechnol       Date:  2010-07-09       Impact factor: 54.908

Review 3.  Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease.

Authors:  Dagmar E Ehrnhoefer; Liza Sutton; Michael R Hayden
Journal:  Neuroscientist       Date:  2011-02-10       Impact factor: 7.519

4.  Large-Scale Targeted Proteomics Using Internal Standard Triggered-Parallel Reaction Monitoring (IS-PRM).

Authors:  Sebastien Gallien; Sang Yoon Kim; Bruno Domon
Journal:  Mol Cell Proteomics       Date:  2015-03-09       Impact factor: 5.911

5.  A Strategy to Combine Sample Multiplexing with Targeted Proteomics Assays for High-Throughput Protein Signature Characterization.

Authors:  Brian K Erickson; Christopher M Rose; Craig R Braun; Alison R Erickson; Jeffrey Knott; Graeme C McAlister; Martin Wühr; Joao A Paulo; Robert A Everley; Steven P Gygi
Journal:  Mol Cell       Date:  2017-01-05       Impact factor: 17.970

6.  Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity.

Authors:  Birgit Schilling; Juliette Gafni; Cameron Torcassi; Xin Cong; Richard H Row; Michelle A LaFevre-Bernt; Michael P Cusack; Tamara Ratovitski; Ricky Hirschhorn; Christopher A Ross; Bradford W Gibson; Lisa M Ellerby
Journal:  J Biol Chem       Date:  2006-06-16       Impact factor: 5.157

7.  Kinase inhibitors modulate huntingtin cell localization and toxicity.

Authors:  Randy Singh Atwal; Carly R Desmond; Nicholas Caron; Tamara Maiuri; Jianrun Xia; Simonetta Sipione; Ray Truant
Journal:  Nat Chem Biol       Date:  2011-05-29       Impact factor: 15.040

8.  Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation.

Authors:  Lauren S Havel; Chuan-En Wang; Brandy Wade; Brenda Huang; Shihua Li; Xiao-Jiang Li
Journal:  Hum Mol Genet       Date:  2011-01-18       Impact factor: 6.150

9.  Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons.

Authors:  Emilie Colin; Diana Zala; Géraldine Liot; Hélène Rangone; Maria Borrell-Pagès; Xiao-Jiang Li; Frédéric Saudou; Sandrine Humbert
Journal:  EMBO J       Date:  2008-07-10       Impact factor: 11.598

10.  Phosphorylation of mutant huntingtin at serine 116 modulates neuronal toxicity.

Authors:  Erin E Watkin; Nicolas Arbez; Elaine Waldron-Roby; Robert O'Meally; Tamara Ratovitski; Robert N Cole; Christopher A Ross
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

View more
  17 in total

Review 1.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

2.  Design and characterization of mutant and wildtype huntingtin proteins produced from a toolkit of scalable eukaryotic expression systems.

Authors:  Rachel J Harding; Peter Loppnau; Suzanne Ackloo; Alexander Lemak; Ashley Hutchinson; Brittany Hunt; Alex S Holehouse; Jolene C Ho; Lixin Fan; Leticia Toledo-Sherman; Alma Seitova; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2019-03-06       Impact factor: 5.157

3.  Interaction of huntingtin with PRMTs and its subsequent arginine methylation affects HTT solubility, phase transition behavior and neuronal toxicity.

Authors:  Tamara Ratovitski; Mali Jiang; Robert N O'Meally; Priyanka Rauniyar; Ekaterine Chighladze; Anikó Faragó; Siddhi V Kamath; Jing Jin; Alexey V Shevelkin; Robert N Cole; Christopher A Ross
Journal:  Hum Mol Genet       Date:  2022-05-19       Impact factor: 5.121

4.  Post-translational modifications clustering within proteolytic domains decrease mutant huntingtin toxicity.

Authors:  Nicolas Arbez; Tamara Ratovitski; Elaine Roby; Ekaterine Chighladze; Jacqueline C Stewart; Mark Ren; Xiaofang Wang; Daniel J Lavery; Christopher A Ross
Journal:  J Biol Chem       Date:  2017-09-27       Impact factor: 5.157

5.  Huntingtin-mediated axonal transport requires arginine methylation by PRMT6.

Authors:  Alice Migazzi; Chiara Scaramuzzino; Eric N Anderson; Debasmita Tripathy; Ivó H Hernández; Rogan A Grant; Michela Roccuzzo; Laura Tosatto; Amandine Virlogeux; Chiara Zuccato; Andrea Caricasole; Tamara Ratovitski; Christopher A Ross; Udai B Pandey; José J Lucas; Frédéric Saudou; Maria Pennuto; Manuela Basso
Journal:  Cell Rep       Date:  2021-04-13       Impact factor: 9.423

6.  The cryo-electron microscopy structure of huntingtin.

Authors:  Qiang Guo; Jingdong Cheng; Manuel Seefelder; Tatjana Engler; Günter Pfeifer; Patrick Oeckl; Markus Otto; Franziska Moser; Melanie Maurer; Alexander Pautsch; Wolfgang Baumeister; Rubén Fernández-Busnadiego; Stefan Kochanek
Journal:  Nature       Date:  2018-02-21       Impact factor: 49.962

Review 7.  Strategies to Investigate Ubiquitination in Huntington's Disease.

Authors:  Karen A Sap; Eric A Reits
Journal:  Front Chem       Date:  2020-06-11       Impact factor: 5.221

Review 8.  How Do Post-Translational Modifications Influence the Pathomechanistic Landscape of Huntington's Disease? A Comprehensive Review.

Authors:  Beata Lontay; Andrea Kiss; László Virág; Krisztina Tar
Journal:  Int J Mol Sci       Date:  2020-06-16       Impact factor: 5.923

9.  Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeutics.

Authors:  Sergey S Akimov; Mali Jiang; Amanda J Kedaigle; Nicolas Arbez; Leonard O Marque; Chelsy R Eddings; Paul T Ranum; Emma Whelan; Anthony Tang; Ronald Wang; Lauren R DeVine; Conover C Talbot; Robert N Cole; Tamara Ratovitski; Beverly L Davidson; Ernest Fraenkel; Christopher A Ross
Journal:  Hum Mol Genet       Date:  2021-11-30       Impact factor: 5.121

Review 10.  Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities.

Authors:  Sarah J Tabrizi; Michael D Flower; Christopher A Ross; Edward J Wild
Journal:  Nat Rev Neurol       Date:  2020-08-14       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.